Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base

30 May 2025

Abstract excerpt

Therapeutic monoclonal antibodies can prevent severe disease in SARS-CoV-2 exposed individuals. However, currently circulating virus variants have evolved to gain significant resistance to nearly all neutralizing human immune system-derived therapeutic monoclonal antibodies that had previously been emergency-authorized for use in the clinic. Here, we describe the discovery of a panel of single-domain antibodies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40447603
DOI: 10.1038/s41467-025-60250-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its basePMID 40447603Read ↗

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spikeSemantic proximity Read ↗

Broadly neutralizing antibodies against COVID-19Semantic proximity Read ↗

An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimerSemantic proximity Read ↗

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domainSemantic proximity Read ↗

Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variantsSemantic proximity Read ↗

Dissociation kinetics and avidity gate SARS-CoV-2 neutralization by HR2 stem helix antibodiesSemantic proximity Read ↗

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibodySemantic proximity Read ↗

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognitionSemantic proximity Read ↗

Structural Insights into the SARS-CoV-2 Spike Protein and Its Implications for Antibody Resistance.Semantic proximity Read ↗

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.Semantic proximity Read ↗

Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody CocktailSemantic proximity Read ↗

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.